The level of melatonin and serotonin neurohormones in blood serum in patients with non-alcoholic fatty liver disease and kidney lesions infected with COVID-19 virus

Abstract. Background. Research aimed at determining the possible mechanisms of progression in the damage to various organs and systems against the background of COVID-19 infection is an urgent, not thoroughly studied issue in contemporary clinical medicine. The purpose was to determine the peculiarities of changes in serum melatonin (MT) and serotonin (ST) neurohormone levels in patients with non-alcoholic fatty liver disease (NAFLD) and kidney damage infected with the COVID-19 virus. Materials and methods. 84 patients with NAFLD (steatohepatitis) combined with increased body mass index were examined. NAFLD patients were divided into two groups depending on the presence or absence of type 2 diabetes mellitus (DM), and namely: Group 1 included 34 NAFLD and insulin resistance (IR) patients; Group 2 comprised 38 patients with NAFLD and type 2 DM. All examined patients were tested for MT and ST levels in blood serum. Results. There was a significant decrease in serum MT level in both examined groups — by 2.2 and 3.2 times respectively in group 1 and 2 patients at the time of admission to the hospital. The same trend was identified in the indicators of serum MT level in both groups of patients on day 1 of inpatient treatment (IT) — and namely, its decrease by 1.5 and 2.3 times. Revealed a correlation between the progression of liver damage and the decrease of MT and ST levels in blood serum, which is probably a consequence of its toxic damage against the background of the conducted treatment of patients infected with COVID-19. The decreased serum neurohormone levels also correlate with the insulin level and IR index. There is also a strong correlation between renal damage occurring at the IT stage in NAFLD patients and impaired carbohydrate metabolism during COVID-19 infection and decreased levels of MT and ST in the blood, which is probably a consequence of its toxic damage against the background of COVID-19 infection and kidney damage in these patients. Conclusions. COVID-19 infection and its treatment in NAFLD patients with impaired carbohydrate metabolism lead to impaired renal functional status. In patients with NAFLD and carbohydrate metabolism disorders, a decrease in serum levels of the neurohormones MT and ST was found, which progressively decreased against the background of COVID-19 infection and kidney damage in these patients.

Keywords: non-alcoholic fatty liver disease; type 2 diabetes mellitus; kidney damage; COVID-19; melatonin; serotonin

Introduction

In December 2019, a series of unknown origin cases of acute respiratory illness occurred in Wuhan, Hubei Province, China. High-throughput sequencing showed that the disease was caused by named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). On February 11, 2020, the World Health Organization officially changed the name of the disease caused by SARS-CoV-2 to coronavirus disease 2019 (COVID-19). Although diffuse alveolar damage and acute respiratory failure were the main features of COVID-19, the involvement of other organs needed to be explored. After lung infection, the virus may enter the blood, accumulate in kidney, and cause damage to resident renal cells. Indeed, COVID-19 RNA was found in the plasma of 15% of patients by real-time polymerase chain reaction. Of note, it is reported showed that 6.7% of
patients with SARS developed acute kidney injury (AKI), and the mortality of those with AKI was 91.7 %. Thus, understanding how the kidney is affected by SARS-CoV-2 is urgently warranted [1].

A recent prospective cohort study reviewed kidney disease among 701 patients who were treated for COVID-19 in Wuhan, China. Those patients with kidney disease had higher in-hospital mortality; moreover, there was evidence of hematuria in 26.7 % and proteinuria in 43.9 % of patients in their cohort. Although kidney tissue was not examined, the authors postulated potential multifactorial renal injury, including direct cytotoxic effects (via viral entry through angiotensin-converting enzyme 2 receptors expressed on tubular epithelium), as well as tubular injury from cytokine storm, shock, and rhabdomyolysis [2]. High comorbidity in this case increases the risk of kidney damage in COVID-19 (chronic kidney disease, heart failure, liver disease, diabetes mellitus, acute kidney damage in the anamnesis, patient age > 65 years) [3].

It is unlikely that SARS-CoV-2 directly causes primary liver injury but the mechanisms by which SARS-CoV-2 affects the liver are not well defined. Postmortem studies report moderate microvascular steatosis with mild lobular and portal activity but no obvious inflammatory cell infiltration or typical liver cell necrosis. Ultrastructural examination of 2 COVID-19 patients identified typical, spike structure coronavirus particles in the cytoplasm of hepatocytes accompanied by massive hepatic apoptosis, some binuclear hepatocytes and scanty CD4+ and CD8+ lymphocytes that were considered indicative of a typical viral infection. A proposed mechanism of direct liver injury is by direct cytoxicity from viral replication in liver cells [4]. The most significant modifiable risk factors for the poor prognosis from COVID-19 are obesity and metabolic disease. These findings, such as nonalcoholic fatty liver disease (NAFLD), cause the activation of inflammatory pathways. It suggests that NAFLD can play a key role as a risk factor in the severity and prognosis of coronavirus disease 2019 patients [5].

Therefore, research aimed at determining the possible mechanisms of progression in the damage to various organs and systems against the background of COVID-19 infection is an urgent, not thoroughly studied issue in contemporary clinical medicine. The study of the influence of neurohormones, such as melatonin (MT) and its precursor — serotonin (ST). Nowadays, it is possible to distinguish 7 families of serotonin receptors, which trigger intracellular processes affecting the excitation of other mediator systems and manifest metabolitotopic effects, i.e., they activate the cascade of intracellular biochemical reactions in the target cells [6]. Melatonin is secreted by the epithysis as well as the cells of the diffuse neuroendocrine system (APUD system) and influences the modulation of metabolic processes in the body [7].

Nowadays, there have been several studies, demonstrating the ability of melatonin to alleviate inflammation and the intensity of “cytokine storms” in patients with COVID-19. Melatonin supplements are effective in patients hospitalized with COVID-19 due to decreased vascular permeability, and they can be used in combination with COVID-19 medications and treatments [8]. Therefore, the study of the levels of MT and ST neurotransmitters involved in the regulation of the immune response, resistance to stress, functioning of various organs and systems, especially in patients with comorbid pathology, and namely NAFLD, type 2 diabetes, obesity, is an urgent issue of clinical medicine, especially among individuals infected with COVID-19.

The purpose of the study was to determine the peculiarities of changes in serum melatonin and serotonin neurohormone levels in patients with NAFLD and kidney damage infected with the COVID-19 virus.

Materials and methods

A complex examination of the patients was carried out on the clinical base of the Department of Propaedeutics of Internal Medicine, Faculty of Medicine, State Higher Educational Establishment “UzhNU”. The scientific study included 72 patients with non-alcoholic fatty liver disease (steatohepatitis) combined with increased body mass index (BMI) (overweight or obesity of varying severity) and carbohydrate metabolism disorders, who were treated in the department for COVID-19 infected patients at the CNE “TRCH named after A. Novak” (TRD) from October 2020 to 2022 and had a confirmed diagnosis of COVID-19 pneumonia (positive polymerase chain reaction (PCR test) to SARS-CoV-2 RNA (RdRP SARS-CoV-2 gene, E SARS-CoV-2 gene), as well as “ground-glass opacity” lung lesion on CT scan with a maximum percentage of lung tissue damage up to 65.0 %) and did not require connecting the patients to an artificial lung ventilation apparatus. It was decided to hospitalize these patients due to the high risk of possible complications and a more severe course of viral infection against the background of comorbid pathology. Patients were diagnosed (determination of blood levels of procalcitonin, interleukin-6, C-reactive protein, ferritin, D-dimer) and treated (administration of antiviral therapy, glucocorticoids, anticoagulants, vitamin D3, zinc medication, and antibiotic therapy) according to the standards of medical treatment for COVID-19 infections. It should be noted that the examined NAFLD patients were not diagnosed with kidney damage before admission to the hospital due to the COVID-19 infection.

Exclusion criteria from the study included an extremely severe condition of patients infected with COVID-19, presence of congenital malformations of the urinary system, acute and chronic glomerulonephritis and pyelonephritis, type 1 diabetes, the presence of alcohol, autoimmune, viral lesions (hepatitis B, C, D viruses) of the liver.

The control group included 20 virtually healthy individuals (12 (60.0 %) were men and 8 (40.0 %) were women. The average age was (49.6 ± 7.1) years).

All studies were performed with the consent of the patients (written consent was obtained from all the patients for the appropriate diagnostic and therapeutic measures), and the methodology was consistent with the Helsinki Decla-
ration of Human Rights, 1975 and its revision of 1983, the Council of Europe Convention on Human Rights and Biomedicine and the legislation of Ukraine.

All examined patients were subjected to investigation by general clinical, anthropometric, instrumental and laboratory methods. To verify the diagnosis, attention was paid to the nature of the complaints and medical history. The anthropometric study involved determining height, weight, waist circumference, and calculating the BMI.

All patients underwent an ultrasound examination of the abdominal cavity and kidneys according to the standard methodology. At the beginning of the inpatient phase of treatment (day 1), as well as on day 10 of inpatient treatment (IT), standard general and biochemical tests were performed in blood serum to determine the functional status of the liver (alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBL) and its fractions, alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT)), kidneys (creatinine level, urea), lipid and carbohydrate metabolism parameters (glucose, insulin, glycosylated hemoglobin (HbA1c, %), insulin resistance index was calculated (IR-HOMA)). The examined patients were also subjected to cystatin C (CysC) level determination via enzyme multiplied immunoassay using “BioVendor” test system (the Czech Republic).

All examined patients were also tested for melatonin (MT) levels in blood serum via radioimmune analysis and the usage of test systems (LDN Labor Diagnostika Nord GmbH, Germany). Blood sampling was performed at the same time from 7:30 to 8:00 a.m. in both examined patients and healthy individuals in the control group, considering the fact that melatonin levels are related to the circadian rhythm. Serotonin (ST) levels in blood serum were also determined by high-performance liquid chromatography on an Agilent 1100 chromatograph, using the Agilent Technologies (USA) test system.

The diagnosis of NAFLD was performed according to the criteria of the unified clinical protocol (Order of the Ministry of Health of Ukraine № 826 dated 06.11.2014) and EASL-EASD-EASO clinical practice guidelines for the diagnosis and treatment of NAFLD [9]. The degree of liver damage was estimated using surrogate markers of fibrosis with the help of online NAFLD fibrosis score (NFS) calculators. Fibrosis 4 calculator (FIB-4), fibrotest, as well as liver elastometry results.

Type 2 DM was diagnosed according to the IDF recommendations (2005), as well as taking into account the criteria of the unified clinical protocol (order of the Ministry of Health of Ukraine No. 1118 of December 21, 2012) [10]. The severity of type 2 DM was assessed by the HbA1c level (the norm is up to 6.0 %).

To research the functional state of the kidneys in the examined patients, the glomerular filtration rate (GFR) was calculated using the creatinine index, the MDRD (Modification of Diet in Renal Disease) formula and the Cockroft-Gault (CG) formula [11] as well as the formula in which the cystatin C level was applied (GFR_{CysC} = 94.652 × Cys C^{−1.247}) [12].

NAFLD patients were divided into two groups depending on the presence or absence of type 2 DM, and namely:

— Group 1 included 34 NAFLD and insulin resistance (IR) patients (19 (55.9 %) were men, 19 (44.1 %) were women; the average age was (51.7 ± 4.8) years);

— Group 2 comprised 38 patients with NAFLD and type 2 DM (among them 22 (57.9 %) were men and 16 (42.1 %) were women; the average age was (50.2 ± 5.3) years).

The results of the patients’ examination were analyzed and processed using the computer program Statistica 10.0 (StatSoft Inc., USA) applying parametric and nonparametric methods of assessing the results.

Results

All patients under our observation were diagnosed with NAFLD, namely, non-alcoholic steatohepatitis of minimal degree of activity at the time of their admission to the hospital. At the same time, more pronounced changes in transaminase levels at the time of admission for inpatient treatment were diagnosed in group 2 patients. On day 10 of IT, all the patients with COVID-19 infection were diagnosed with increased activity of liver transaminases, as well as total bilirubin level, which, in our opinion, is connected with the toxic influence of prescribed therapy on the patients’ compromised liver, which is confirmed by the increase in GGT level (Table 1).

| Indicator | Control group (n = 20) | Group 1 (n = 34) | Group 2 (n = 38) | 1st day of IT | 10th day of IT | 1st day of IT | 10th day of IT |
|-----------|-----------------------|-----------------|-----------------|--------------|---------------|--------------|---------------|
| ALT, U/L  | 24.7 ± 1.7            | 96.5 ± 3.6**    | 138.7 ± 4.1**   | 147.1 ± 5.3** | 202.6 ± 5.1*** | 108.8 ± 2.9**  | 189.3 ± 4.1**  |
| AST, U/L  | 22.3 ± 1.4            | 64.3 ± 3.1      | 117.1 ± 3.9**   | 111.9 ± 3.7** | 179.9 ± 6.3*** | 106.3 ± 3.1**  | 178.7 ± 3.7*** |
| TBL, mmol/l | 14.6 ± 0.5           | 27.6 ± 1.2      | 37.5 ± 2.0**    | 31.8 ± 2.1   | 41.4 ± 3.8**   | 97.2 ± 4.5**   | 104.5 ± 4.5**  |
| ALP, mmol/l | 72.6 ± 3.4           | 132.7 ± 2.1**   | 172.2 ± 4.8**   | 152.7 ± 4.4** | 189.3 ± 4.1**  | 108.8 ± 2.9**  | 189.3 ± 4.1**  |
| GGT, U/L  | 36.4 ± 3.1            | 67.7 ± 3.5      | 108.8 ± 2.9**   | 93.6 ± 4.5** | 178.7 ± 3.7*** | 108.8 ± 2.9**  | 189.3 ± 4.1**  |

Notes: the difference is statistically significant between the parameters of the control group and the examined patients of groups 1 and 2: * — p < 0.05; ** — p < 0.01; *** — p < 0.001; the difference between the indicators in group 1 patients on days 1 and 10 of IT is statistically reliable: * — p < 0.05; ** — p < 0.01; the difference between the indicators in group 2 patients on days 1 and 10 of IT is statistically reliable: * — p < 0.05; ** — p < 0.01; the difference between the indicators of group 1 and 2 patients on day 1 of IT is statistically reliable: # — p < 0.05; # — p < 0.01; the difference between the indicators in group 1 and 2 patients on the 10th day of IT is statistically reliable: ## — p < 0.05; ## — p < 0.01.
The determination of carbohydrate metabolism indices confirms type 2 DM in group 2 patients and IR in patients examined in group 1 at the time of admission for IT due to COVID-19 infection. The aggravation of acute respiratory infection, as well as the prescription of glucocorticoid drugs to stabilize the patients’ condition, contributed to the increase in blood sugar levels in both examined groups, as well as the progression of hyperinsulinemia in Group 1 patients. Group 2 patients demonstrated a tendency to decrease insulin and C-peptide activity in blood serum on day 10 of IT (Table 2).

At the beginning of the inpatient phase of treatment in the COVID-19-infected patients that we examined, the indicators of renal functional status did not indicate its impairment in patients with NAFLD in combination with IR or type 2 DM. On day 10 of IT, these patients had increased serum creatinine and urea levels, as well as proteinuria and decreased GFR, indicating renal damage against the background of COVID-19 infection. At the same time, the daily proteinuria in patients of both groups differed from that of the control group at the time of admission to the hospital and increased to a maximum of (367.0 ± 2.8) mg/day on the 10th day of IT (p < 0.05) in Group 2 patients (Table 3). All examined patients in both groups also demonstrated erythrocyturia and leukocytyuria against the background of COVID-19 infection, which increased progressively by day 10 of IT.

On day 10 of IT, the determination of GFR revealed a decrease in the filtration capacity of the kidneys in both groups of patients, regardless of the method of its calculation. Consequently, in NAFLD patients with impaired carbohydrate metabolism, acute respiratory infection COVID-19 contributes to the formation of kidney damage.

There was a significant decrease in serum MT level in both examined groups — by 2.2 and 3.2 times respectively in group 1 and 2 patients at the time of admission to the hospital. The same trend was identified in the indicators of serum MT level in both groups of patients on day 1 of IT —

Table 2 — Indicators of Carbohydrate Metabolism in the Examined Patients’ Blood Serum

| Indicator          | Control group (n = 20) | Examined patients |
|--------------------|------------------------|-------------------|
|                    | 1st day of IT (n = 34) | 10th day of IT (n = 34) |
| Fasting blood glucose, mmol/l | 4.6 ± 0.5 | 5.3 ± 0.2 |
| HbA1c, %           | 4.2 ± 0.3 | 5.1 ± 0.4** |
| Insulin, U/L       | 9.2 ± 0.6 | 23.2 ± 1.2** |
| C-peptide, ng/ml   | 4.1 ± 0.3 | 12.1 ± 1.4** |
| HOMA-IR            | 1.7 ± 0.4 | 5.6 ± 0.6** |

Notes: the difference is statistically reliable between the parameters of the control group and the examined patients of groups 1 and 2: * — p < 0.05; ** — p < 0.01; *** — p < 0.001; the difference between the indicators in group 1 patients on days 1 and 10 of IT is statistically reliable: * — p < 0.05; ** — p < 0.01; the difference between the indicators in group 2 patients on days 1 and 10 of IT is statistically reliable: * — p < 0.05; ** — p < 0.01; the difference between the indicators of group 1 and 2 patients on day 1 of IT is statistically reliable: — p < 0.05; ** — p < 0.01; the difference between the indicators in group 1 and 2 patients on the 10th day of IT is statistically reliable: t — p < 0.05; ^ — p < 0.01.

Table 3 — Indicators of the Renal Functional State in the Examined Patients

| Indicator          | Control group (n = 20) | Examined patients |
|--------------------|------------------------|-------------------|
|                    | 1st day of IT (n = 34) | 10th day of IT (n = 34) |
| Creatinine, µmol/l | 81.3 ± 2.5 | 104.7 ± 3.4 |
| Urea, mmol/l       | 5.3 ± 0.8 | 6.6 ± 0.6 |
| Cys C, mg/l        | 0.75 ± 0.04 | 1.06 ± 0.05* |
| Proteinuria, mg/day| 53.3 ± 4.1 | 118.0 ± 4.8** |
| GFR MDRD, ml/min per 1.73 m² body surface area | 105.1 ± 2.8 | 88.0 ± 3.2 |
| GFR CG, ml/min per 1.73 m² of body surface | 110.1 ± 3.2 | 97.7 ± 2.4 |
| GFR Cys C, ml/min per 1.73 m² of body surface | 106.7 ± 2.2 | 95.8 ± 2.4 |

Notes: the difference is statistically reliable between the parameters of the control group and the examined patients of groups 1 and 2: * — p < 0.05; ** — p < 0.01; the difference between the indicators in group 1 patients on days 1 and 10 of IT is statistically reliable: * — p < 0.05; the difference between the indicators in group 2 patients on days 1 and 10 of IT is statistically reliable: * — p < 0.05; ** — p < 0.01; the difference between the indicators of group 1 and 2 patients on day 1 of IT is statistically reliable: * — p < 0.05; ** — p < 0.01; the difference between the indicators in group 1 and 2 patients on the 10th day of IT is statistically reliable: t — p < 0.05.
and namely, its decrease by 1.5 and 2.3 times. Both MT and ST levels progressively decreased on day 10 of treatment for COVID-19 infection in NAFLD patients combined with carbohydrate metabolism disorders (Table 4).

We analyzed the relationship between the decrease in serum neurohormone levels and the indicators of the functional state of the liver and kidneys, and carbohydrate metabolism in the patients on day 10 of inpatient treatment (Table 5).

Statistical analysis revealed a correlation between the progression of liver damage and the decrease of MT and ST levels in blood serum, which is probably a consequence of its toxic damage against the background of the conducted treatment of patients infected with COVID-19. The decreased serum neurohormone levels also correlate with the insulin level and insulin resistance index. There is also a strong correlation between renal damage occurring at the IT stage in NAFLD patients and impaired carbohydrate metabolism during COVID-19 infection and decreased levels of MT and ST in the blood, according to GFR MDRD. A more pronounced correlation between changes in the functional state of the kidneys and neurohormone indicators was established in group 2 patients (NAFLD in combination with type 2 diabetes mellitus) mainly when determining GFR by the Cys C index.

### Table 4 — Levels of Neurohormones in the Examined Patients’ Blood Serum

| Indicator       | Control group (n = 20) | Examined patients | 1st day of IT | 10th day of IT | 1st day of IT | 10th day of IT |
|-----------------|-----------------------|-------------------|---------------|----------------|---------------|----------------|
| MT, pg/ml       |                       |                   |               |                |               |                |
| 28.08 ± 0.42    | 12.70 ± 0.15**        | 8.16 ± 0.12**     | 8.67 ± 0.16** | 6.21 ± 0.33*** |
| ST, mcg/L       | 329.7 ± 18.9          | 221.6 ± 8.4†      | 95.9 ± 5.7**  | 145.9 ± 5.6**  | 72.80 ± 3.25*** |

**Notes:** the difference is statistically reliable between the parameters of the control group and the examined patients of groups 1 and 2: * — p < 0.05; ** — p < 0.01; *** — p < 0.001; the difference between the indicators in group 1 patients on days 1 and 10 of IT is statistically reliable: * — p < 0.05; ** — p < 0.01; the difference between the indicators in group 2 patients on days 1 and 10 of IT is statistically reliable: * — p < 0.05; ** — p < 0.01; the difference between the indicators of group 1 and 2 patients on day 1 of IT is statistically reliable: ^ — p < 0.05; ++ — p < 0.01; the difference between the indicators in group 1 and 2 patients on the 10th day of IT is statistically reliable: £ — p < 0.05.

### Table 5 — Correlation of Neurohormone Indicators and Functional State of the Liver and Kidneys, Carbohydrate Metabolism in the Examined Patients

| Indicator                  | MT, pg/ml     | ST, mcg/L    |
|---------------------------|---------------|--------------|
|                           | group 1 (n = 34) | group 2 (n = 38) | group 1 (n = 34) | group 2 (n = 38) |
| ALT, U/L                  | r = 0.70; p < 0.05 | r = 0.84; p < 0.01 | r = 0.80; p < 0.01 | r = 0.82; p < 0.01 |
| AST, U/L                  | r = 0.58; p < 0.05 | r = 0.60; p < 0.01 | r = 0.88; p < 0.01 | r = 0.74; p < 0.05 |
| GGT, U/L                  | —             | r = 0.64; p < 0.05 | —             | r = 0.77; p < 0.01 |
| Fasting blood glucose, mmol/l | —             | r = 0.64; p < 0.05 | r = 0.68; p < 0.05 | r = 0.70; p < 0.05 |
| Insulin, U/L              | —             | r = 0.78; p < 0.01 | r = 0.76; p < 0.01 | r = —0.72; p < 0.05 |
| HOMA-IR                   | r = 0.66; p < 0.05 | r = 0.78; p < 0.01 | r = 0.56; p < 0.05 | —             |
| MDRD, ml/min per 1.73 m² body surface | —             | r = 0.74; p < 0.05 | r = 0.82; p < 0.01 | r = 0.88; p < 0.01 |
| GFR CG, ml/min per 1.73 m² body surface | —             | —             | —             | r = 0.78; p < 0.01 |
| GFR Cys C, ml/min per 1.73 m² body surface | r = —0.80; p < 0.01 | r = 0.88; p < 0.01 | r = 0.76; p < 0.01 | r = 0.94; p < 0.01 |

**Discussion**

The study of the influence of neurotransmitters (MT, ST) on the formation of lesions of various organs and systems during COVID-19 infection is of particular interest, especially in patients with metabolically associated diseases, such as NAFLD, type 2 diabetes, obesity, etc.

The experimental study (Kolyanyk I.A., Herush I.V., 2020) revealed an imbalance of antioxidant system parameters when modelling nephropathy with folic acid, which is probably due to increased free-radical damage to biomolecules. The administration of melatonin for 7 days contributes to the normalization of indicators of the antioxidant system in the liver of rats with nephropathy, which is due to its ability to directly neutralize toxic compounds and activate antioxidant enzymes [13]. Another experimental study (Kryvchanska M.I. et al., 2016) also studied the effect of melatonin on the correction of disorders of circadian organization of renal function and deviations of the morphological state of the kidneys caused by propranolol. The studies suggest that exogenous melatonin is able to influence the indicators of the main renal functions, demonstrating a pleiotropic effect [14].

Clinical studies based on the determination of melatonin concentrations in patients with different degrees of renal dysfunction in chronic kidney disease revealed a cor-
relation between total melatonin concentration and GFR. A decrease in melatonin concentration and a disruption in its synthesis rhythm occurred in accordance with the progression of renal dysfunction. In experimental animal models in the formation of pyelonephritis, renal failure, arterial hypertension and diabetes mellitus, a decrease in the severity of oxidative stress, inhibition of chronic inflammation and limitation of apoptosis with increasing concentrations of melatonin were demonstrated. The administration of exogenous melatonin promotes a decrease in urine osmolarity, urinary concentration of sodium and potassium ions, and an increase in GFR. All these effects are associated with a decrease in parenchymal cell damage, fibrosis and the decrease in proteinuria under the influence of melatonin [15].

The important role of ST in the regulation of circadian rhythm of renal function has also been proved [16]. In the experiment serotonin administration under conditions of bilateral vagotomy promotes the restoration of the organ blood supply, including glomeruli and tubules, prevents the development of proximal tubule epithelium necrosis. Thus, the activation of the serotonergic system can compensate for the impaired parasympathetic innervation of the kidney [17].

The findings we obtained indicate the decrease of serum MT and ST levels in NAFLD patients and impaired carbohydrate metabolism with the most pronounced deviation from the norm in NAFLD patients with type 2 diabetes mellitus. Impaired renal function developed in the patients with COVID-19 infection, as well as due to its therapy, contributes to an even more progressive decrease in these neurohormones in the blood serum. A direct correlation was established between the decreased serum levels of ST and MT rohormones in the blood serum. A direct correlation was established between the decreased serum levels of ST and MT.

Conclusions

1. COVID-19 infection and its treatment in NAFLD patients with impaired carbohydrate metabolism lead to impaired renal functional status.

2. In patients with NAFLD and carbohydrate metabolism disorders, a decrease in serum levels of the neurohormones melatonin and serotonin was found, which progressively decreased against the background of COVID-19 infection and kidney damage in these patients.

References

1. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020 May;97(5):829-838. doi: 10.1016/j.kint.2020.03.005.

2. Peleg Y, Kadosse S, D’Agati V, et al. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep. 2020 Apr 28;5(6):940-945. doi: 10.1016/j.ekir.2020.04.017.

3. Selby NM, Forni LG, Laing CM, et al. Covid-19 and acute kidney injury in hospital; summary of NICE guidelines. BMJ. 2020 May 26;369:m1963. doi: 10.1136/bmj.m1963.

4. Hamid S, Alvares da Silva MR, Burak KW, et al. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021 Jun;55(1):1-11. doi: 10.1097/MCG.0000000000001459.

5. Ziaee A, Azarkar G, Ziaee M. Role of fatty liver in coronavirus disease 2019 patients’ disease severity and hospitalization length: a case-control study. Eur J Med Res. 2021 Sep 26;26(1):115. doi: 10.1186/s40001-021-00590-y.

6. Popov SS, Pushkov AN, Esaulenko IE, Popova TN, Agarkov AA, Kuptsova GN. Antipapotic effect of melatonin in nonalcoholic steatohepatitis developing in patients with type 2 diabetes mellitus. Clinical endocrinology. 2018;63(3):162-168. doi: 10.14341/probi2017633162-168.

7. Zaichenko AV, Gorchakova NA. Serotonin: from neuromediator to drug. Bulletin of problems in biology and medicine. 2017;(137):49-56.

8. Mamchur VI, Nosivce DS, Khomyak EV. Melatonin as a secondary therapy for COVID-19. Family medicine. 2020(89):13-19.

9. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.

10. Ministry of Health of Ukraine. Order 1118 dated Dec 21, 2021. Type 2 Diabetes Mellitus: Unified clinical protocol for primary and secondary (specialized) medical care. Kyiv; 2012. 118p. (in Ukrainian).

11. Classification of diseases of the urinary system. Ukrainian Journal of Nephrology and Dialysis. 2018;(57):3-23. (in Ukrainian).

12. Karstila K, Harmoinen AP, Lehtimäki TJ, Korpela MM, Mustonen JT, Saha HH. Measurement of the kidney function in patients with rheumatoid arthritis: plasma cystatin C versus 51Cr-EDTA clearance. Nephron Clin Pract. 2008;108(4):284-90. doi: 10.1159/000127362.

13. Koliyanik IO, Gerash VV. Melatonin effect on the liver antioxidant system of rats with experimental nephropathy. Bulletin of Medical and Biological Research. 2020(4):37-41. doi: 10.11603/bmbr.2076-6290.2020.4.11802.

14. Kryvchanskas MI, Ryznichuk MO, Pishak VP. Morphological and functional changes in kidneys caused by propranolol: effects of melatonin. Morphologia. 2016;3(10):197-198. doi: 10.26641/1997-9665.2016.3.196-198.

15. Kondratiev VE, Petrova AS, Karpenko OV. Characterization of melatonin-forming function of pineal gland in patients with end-stage chronic kidney disease. Clinical endocrinology and endocrine surgery. 2019(4):94-102. doi: 10.30978/CEES-2019-4-94.

16. Dotyuk LG, Kashirn IG, Boichuk TM. Intrarenal mechanisms of circadian rhythm kidney function regulation. Medical Chemistry. 2012; 4 (2):78-81.

17. Lychkova AE, Hoschenko YuA, Osipov PG, Fentisov VV. The effect of serotonin on structural state of kidneys (Literature review and own data). Scientific papers. Naucnye vedomosti Belgorodskogo gosudarstvennogo universiteta: Medicina, farmacia. 2016;118(2):22-26.
Ревізія. Актуальність. Дослідження, спрямовані на визначення можливих механізмів прогресування ушкоджень різних органів і систем на тлі інфікування COVID-19, є актуальними, не до кінця вивченими питаннями сучасної клінічної медицини. Мета. Визначити особливості зміни рівня нейрогормонів мелатоніну (МТ) та серотоніну (СТ) у сироватці крові у хворих на неалкогольну жирову хворобу печінки (НАЖХП) та ураження нирок, інфікованих вірусом COVID-19. Матеріали та методи. Під нашим спостереженням знаходилися 72 хворі на НАЖХП (стеатогепатит) у поєднанні із збільшенням індексу маси тіла. Хворих на НАЖХП поділено на дві групи залежно від наявності чи відсутності цукрового діабету 2 типу, а саме: у 1 групу увійшло 34 хворі на НАЖХП з інсулінорезистентністю (ІР); 2 групу становили 38 хворих з НАЖХП та цукровим діабетом 2 типу. Усім обстеженим хворим проведено визначення рівня МТ та СТ у сироватці крові. Результати. Встановлено суттєве зниження рівня МТ у сироватці крові в обох групах обстежених — у 2,2 та у 3,2 раза відповідно у хворих 1 та 2 групи на момент надходження в лікарню. Така ж тенденція виявлена і в показниках СТ у сироватці крові у хворих обох груп на 1 день стаціонарного лікування — а саме його зниження в 1,5 та 2,3 раза. Виявили залежність між прогресуванням ураження печінки та зменшенням рівня МТ та СТ у сироватці крові. Зменшений рівень нейрогормонів у сироватці крові також корелює з рівнем інсуліну та індексом інсулінорезистентності. Між ураженням нирок, що виникає на етапі стаціонарного лікування у хворих на НАЖХП з порушеннями вуглеводного обміну при інфікуванні COVID-19, та зменшенням рівня МТ та СТ крові існує сильна кореляційна залежність за швидкістю клубочкової фільтрації за MDRD (r = 0,88; p < 0,01, та r = 0,94; p < 0,01 відповідно). Висновки. Інфекція COVID-19 та її лікування у хворих на НАЖХП з порушеннями вуглеводного обміну призводить до змін функціонального стану нирок. У хворих на НАЖХП з порушеннями вуглеводного обміну встановлено зменшення рівнів нейрогормонів МТ та СТ у сироватці крові, що прогресивно зменшується на фоні інфікування COVID-19 та ураження нирок у даних пацієнтів. Ключові слова: неалкогольна жирова хвороба печінки; цукровий діабет 2 типу; ураження нирок; COVID-19; мелатонін; серотонін.